Buradasınız

Bifosfonatların Pediatrik Nefrolojide Kullanımı Pediatride Bifosfonatlar

Use of Biphosphonates in Pediatric Nephrology Biphosphonates in Pediatric

Journal Name:

Publication Year:

DOI: 
10.5262/tndt.2011.1002.03

Keywords (Original Language):

Abstract (2. Language): 
Biphosphonates (BP), synthetic analogues of inorganic pyrophosphate, potently inhibit skeletal resorption by suppressing the recruitment and activity of osteoclasts and shortening their life span and decreasing bone loss. They are now well established as the major drugs used for the treatment of bone disease associated with excessive resorption such as Paget’s disease, metastatic bone disease and osteoporosis, and refractory hypercalcemia in adults. Over the past decade, BP use in patients with various forms of kidney disease has become widespread. Increasingly, BP are being administered to children and have been reported to improve clinical outcomes and augment bone mass in conditions such as osteogenesis imperfecta, juvenile osteoporosis and fibrous dysplasia. There have been few clinical trials in children to treat bone loss, such as in glucocorticoid-induced osteoporosis and renal osteodystrophy, resulting from renal disease or rheumatologic conditions. The aim of this review was to evaluate the currently available evidence for the effectiveness and safety of BP in children with renal and rheumatological diseases.
Abstract (Original Language): 
Bifosfonatlar (BP) sentetik pirofosfat analoğu bileşiklerdir. Kemik yapımı sırasında osteoklast baskılanmasına yol açarak onların sayı ve işlevlerini azaltır, yaşam süresini kısaltır ve kemik rezorpsiyonunu önlerler. Erişkinlerde aşırı kemik rezorpsiyonuyla giden Paget hastalığı, metastatik kemik hastalığı, osteoporoz ve dirençli hiperkalsemi tedavisindeki etkileri iyi bilinmektedir. Son yıllarda kronik böbrek hastalıkları ve romatolojik hastalıklarda kullanımı yaygınlaşmıştır. Bifosfonatların pediatride kullanımı osteogenesis imperfekta, juvenil osteoporoz, fibröz displazi gibi kemik rezorpsiyonuyla seyreden hastalıklarda başlamış, klinik bulguları düzelttiği ve kemik kitlesini arttırdığı bildirilmiştir. Çocuklarda kronik böbrek hastalıklarında ve romatolojik hastalıklarda, özellikle glukokortikoid kullanımına bağlı osteoporoz tedavisinde yararlı olduğunu gösteren az sayıda çalışma vardır. Bu derleme ile çocukluk çağı böbrek hastalıklarında BP’ların kullanımı ile ilgili veriler incelenmiş, kullanım alanları, etkinliği ve yan etkileri değerlendirilmiştir.
132-141

REFERENCES

References: 

1. Graham R, Russell G: Bisphosphonates: Mode of action and
pharmacology. Pediatrics 2007; 119: 150-162
2. Fleisch H: Biphosphonates in osteoporosis. Eur Spine J 2003; 12:
142-146
3. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Langue G, Travers
R: Cyclic administration of pamidronate in children with severe
osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952
4. Glorieux FH: The use of bisphosphonates in children with
osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001; 14:
1491-1495
5. Glorieux FH: Experience with bisphosphonates in osteogenesis
imperfecta. Pediatrics 2007; 119: 163-165
6. Shoemaker LR: Expanding role of bisphosphonate therapy in
children. J Pediatr 1999; 134: 264-267
7. Dunstan CR, Felsenberg D, Seibel MJ: Therapy insight: The risks
and benefits of bisphosphonates for the treatment of tumor-induced
bone disease. Nature Clinical Practice Oncology 2007; 4: 42-55
8. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston
SR: Systematic review of role of bisphosphonates on skeletal
morbidity in metastatic cancer. BMJ 2003; 327: 469-472
9. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE:
Comparison of the effects of intravenous pamidronate and oral
clodronate on symptoms and bone resorption in patients with
metastatic bone disease. Ann Oncol 2001; 12: 1433-1438
10. Inoue Y, Shimojo N, Suzuki S, Arima T, Tomiita M, Minagawa M,
Kohno Y: Efficacy of intravenous alendronate for the treatment of
glucocorticoid-induced osteoporosis in children with autoimmune
diseases. Clin Rheumatol 2008; 27: 909-912
11. Bachrach LK, Ward LM: Clinical review 1: Bisphosphonate use in
childhood osteoporosis. J Clin Endocrinol Metab 2009; 94: 400-409
12. Allgrove J: Biphosphonates. Arch Dis Child 1997; 76: 73-75
13. Rodan GA, Fleisch HA: Bisphosphonates: Mechanisms of action. J
Clin Invest 1996; 97: 2692-2696
14. Odvina CV, Zerwekhe JE, Rao DS, Malouf N, Gottschalk FA, Pak
CY: Severely suppressed bone turnover: A potential complication of
alendronat therapy. J Clin Endocrinol Metab 2005; 90: 1294-1301
15. Lin JH: Bisphosphonates: a review of their pharmacokinetic
properties. Bone 1996; 18: 75-85
139
Yıldız N ve Alpay H: Bifosfonatların Pediatrik Nefrolojide Kullanımı
Pediatride Bifosfonatlar
Türk N efroloji D iyaliz ve Transplantasyon D ergisi
Turkish Nephrology, Dialysis and Transplantation Journal
Turk Neph Dial Transpl 2011; 20 (2): 132-141
16. Rodd C: Bisphosphonates in dialysis and transplantation patients:
Efficacy and safety issues. Peritoneal Dialysis International 2001;
21:256-260
17. Tanvetyanon T, Stiff PJ: Management of the adverse effects
associated with intravenous bisphosphonates. Ann Oncol 2006; 17:
897-907
18. Aström E, Söderhäll S: Beneficial effect of long term intravenous
bisphosphonate treatment of osteogenesis imperfecta. Arch Dis
Child 2002; 86: 356-364
19. Papapoulos SE, Cremers SC: Prolonged bisphosphonate release
after treatment in children. N Engl J Med 2007; 356: 1075-1076
20. Acott PD, Wong JA, Crocker JF, Lang B, O’Regan P, Renton KW:
Pamidronate distribution in pediatric renal and rheumatologic
patients. Eur J Clin Pharmacol 2006; 62: 1013-1019
21. Cunningham J: Bisphosphonates in the renal patient. Nephrol Dial
Transplant 2007; 22: 1505-1507
22. Shaw NJ: Management of osteoporosis in children. Eur J Endocrinol
2008; 159: 33-39
23. Munns CFJ, Cowell CT: Prevention and treatment of osteoporosis
in chronically ill children. J Musculoskelet Neuronal Interact 2005;
5: 262-272
24. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH:
Effect of intermittent cyclical etidronate therapy on bone mass and
fracture rate in women with postmenopausal osteoporosis. N Engl J
Med 1990; 322: 1265-1271
25. Steelman J, Zeitler P: Treatment of symptomatic pediatric
osteoporosis with cyclic single-day intravenous pamidronate
infusions. J Pediatr 2003; 142: 417-423
26. Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T,
Horio M, Imai E, Hori M, Ito T: Risedronate, an effective treatment
for glucocorticoid-induced bone loss in CKD patients with or
without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial
Transplant 2007; 22: 1601-1607
27. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Kushiyama
T, Higashi K, Hyodo N, Yamamoto K, Suzuki S, Miura S: Effect
of risedronate on high-dose corticosteroid-induced bone loss in
patients with glomerular disease. Nephrol Dial Transplant 2007; 22:
1593-1600
28. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T: Effects of
once-weekly oral alendronate on bone in children on glucocorticoid
treatment. Rheumatology 2005; 44: 813–818
29. Thornton J, Ashcroft DM, Mughal MZ, Elliott RA, O’Neill TW,
Symmons D:Systematic review of effectiveness of bisphosphonates
in treatment of low bone mineral density and fragility fractures in
juvenile idiopathic arthritis. Arch Dis Child 2006; 91: 753-761
30. Sumník Z, Land C, Rieger-Wettengl G, Körber F, Stabrey
A, Schoenau E: Effect of pamidronate treatment on vertebral
deformity in children with primary osteoporosis. A pilot study using
radiographic morphometry. Horm Res 2004; 61: 137-142
31. Zacharin M: Current advances in bone health of disabled children.
Curr Opin Pediatr 2004; 16: 545-551
32. King W, Levin R, Schmidt R, Oestreich A, Heubi JE: Prevalence of
reduced bone mass in children and adults with spastic quadriplegia.
Dev Med Child Neurol 2003; 45: 12-16
33. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT,
Bachrach SJ: Bisphosphonates to treat osteopenia in children with
quadriplegic cerebral palsy: A randomized, placebo-controlled
clinical trial. J Pediatr 2002; 141: 644-651
34. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni
A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi
ML, Falcini F: Efficacy and safety of alendronate for the treatment
of osteoporosis in diffuse connective tissue diseases in children:
A prospective multicenter study. Arthritis Rheum 2000; 43:
1960-1966
35. Cimaz R, Gattorno M, Sormani MP, Falcini F, Zulian F, Lepore
L, Bardare M, Chiesa S, Corona F, Dubini A, Lenhardt A, Martini
G, Masi L, Bianchi ML: Changes in markers of bone turnover and
inflammatory variables during alendronate therapy in pediatric
patients with rheumatic diseases. J Rheumatol 2002; 29: 1786-1792
36. Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S,
Rogol AD, Wilson TA: Bisphosphonate treatment of pediatric bone
disease. Pediatr Endocrinol Rev. 2005; 3: 87-96
37. Acott PD, Wong JA, Lang BA, Crocker JF: Pamidronate treatment
of pediatric fracture patients on chronic steroid therapy. Pediatr
Nephrol 2005; 20: 368-373
38. Stewart AF: Clinical practice. Hypercalcemia associated with
cancer. N Engl J Med 2005; 352: 373-379
39. Sargent JT, Smith OP: Haematological emergencies managing
hypercalcaemia in adults and children with haematological
disorders. Br J Haematol 2010; 149: 465-477
40. Mathur M, Sykes JA, Saxena VR, Rao SP, Goldman GM: Treatment
of acute lymphoblastic leukemia-induced extreme hypercalcemia
with pamidronate and calcitonin. Pediatr Crit Care Med 2003; 4:
252-255
41. Chatterjee M, Speiser PW: Pamidronate treatment of hypercalcemia
caused by vitamin D toxicity. J Pediatr Endocrinol Metab 2007; 20:
1241-1248
42. Kerdudo C, Aerts I, Fattet S, Chevret L, Pacquement H, Doz F,
Michon J, Garabedian M, Orbach D: Hypercalcemia and childhood
cancer: A 7-year experience. J Pediatr Hematol Oncol 2005; 27: 23-
27
43. Auron A, Tal L, Srivastava T, Alon US: Reversal of hypercalcemic
acute kidney injury by treatment with intravenous bisphosphonates.
Pediatr Nephrol. 2009; 24: 613-617
44. Bereket A, Erdogan T: Oral Bisphosphonate therapy for vitamin D
intoxication of the infant. Pediatrics 2003; 111: 899-901
45. Freundlich M, Alanzo E, Bellorin-Font E, Weisnger JR: Reduced
bone mass in children with idiopathic hypercalciuria and in their
asymptomatic mothers. Nephrol Dial Transplant 2002; 17: 1396-
1401
46. Penido MG, Lima EM, Marino VS, Tupinamba AL, França A, Souto
MF: Bone alterations in children with idiopathic hypercalciuria at
tthe time of diagnosis. Pediatr Nephrol 2002; 18: 133- 139
Yıldız N ve Alpay H: Bifosfonatların Pediatrik Nefrolojide Kullanımı
Pediatride Bifosfonatlar
140 Turk Neph Dial Transpl 2011; 20 (2): 132-141
Türk N efroloji D iyaliz ve Transplantasyon D ergisi
Turkish Nephrology, Dialysis and Transplantation Journal
47. Schwaderer AL, Cronin R, Mahan JD, Bates CM: Low bone density
in children with hypercalciuria and/or nephrolithiasis. Pediatr
Nephrol 2008; 23: 2209-2214
48. Weisinger JR: Bone loss in hypercalciuria: Cause or consequence?
Am J Kidney Dis 1999; 33: 46-48
49. Srivastava T, Alon US: Pathophysiology of hypercalciuria in
children. Pediatr Nephrol 2007; 22: 1569-1573
50. Garcia-Nieto V, Ferrandez C, Monge M, de Sequera M, Rodrigo
MD: Bone mineral density in pediatric patients with idiopathic
hypercalciuria. Pediatr Nephrol 1997; 11: 578-583
51. Freundlich M, Alon US: Biphosphonates in children with
hypercalciuria and reduced bone mineral density. Pediatr Nephrol
2008; 23: 2215-2250
52. Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY: Reduced bone
formation and relatively increased bone resorbtion in absorptive
hypercalciuria. Kidney Int 2007; 71: 808-815
53. Hamdy NA, McCloskey EV, Brown CB, Kanis JA: Effects of
clodronate in severe hyperparathyroid bone disease in chronic renal
failure. Nephron 1990; 56: 6-12
54. Ala-Houhala I, Saha H, Liukko-Sipi S, Ylitalo P, Pasternack A:
Pharmacokinetics of clodronate in haemodialysis patients. Nephrol
Dial Transplant 1999; 14: 699-705
55. Beigel AE, Rienhoff E, Olbricht CJ: Removal of clodronate by
haemodialysis in end-stage renal disease patients. Nephrol Dial
Transplant 1995; 10: 2266-2268
56. Saha H, Ala-Houhala IO, Liukko-Sipi SH, Ylitalo P, Pasternack AI:
Pharmacokinetics of clodronate in peritoneal dialysis patients. Perit
Dial Int 1998; 18: 204-209
57. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P,
Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P,
Wang G, Malluche H: Prevention of bone loss in renal transplant
recipients: A prospective, randomized trial of intravenous
pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676
58. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A,
Kirste G, Olschewski M, Schollmeyer PJ: Treatment of osteopenia
and osteoporosis after kidney transplantation. Transplantation 1998;
66: 1004-1008
59. Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson
CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna
KL, Bia MJ: Treatment of osteoporosis and osteopenia in long-term
renal transplant patients with alendronate. Am J Transplant 2002; 2:
62-67
60. Giannini S, D’Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante
L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi
G: Alendronate prevents further bone loss in renal transplant
recipients. J Bone Miner Res 2001; 16: 2111-2117
61. El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA,
Ghoneim MA: Treatment of osteopenia and osteoporosis in renal
transplant children and adolescents. Pediatr Transplantation 2004:
8: 357–361
62. Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M:
Differences in nephrotoxicity of intravenous bisphosphonates for
the treatment of malignancy-related bone disease. Onkologie 2006;
29: 534-540
63. Jackson GH: Renal safety of ibandronate. Oncologist 2005; 10:
14-18
64. Grenda R, Karczmarewicz E, Rubik J, Matusik H, Płudowski P,
Kiliszek M, Piskorski J: Bone mineral disease in children after
renal transplantation in steroid-free and steroid-treated patients - a
prospective study. Pediatr Transplant 2010; 15(2): 205-213
65. Chang JT, Green L, Beitz J: Renal failure with the use of zoledronic
acid. N Engl J Med 2003; 349: 1676-1679
66. Brumsen C, Hamdy NA, Papapoulos SE: Long-term effects of
bisphosphonates on the growing skeleton. Studies of young patients
with severe osteoporosis. Medicine 1997; 76: 266-283
67. Rauch F, Travers R, Munns C, Glorieux FH: Sclerotic metaphyseal
lines in a child treated with pamidronate: Histomorphometric
analysis. J Bone Miner Res 2004; 19: 1191-1193
68. Klein GL, Bachrach LK, Holm IA: Effects of pharmacologic agents
on bone in childhood: An editorial overview. Pediatrics 2007; 119:
125-130
69. Chan YY, Bishop NJ: Clinical management of childhood
osteoporosis. Int J Clin Pract 2002; 56: 280-286
70. Hoekman K, Papapoulos SE, Peters AC, Bijvoet OL: Characteristics
and bisphosphonate treatment of a patient with juvenile osteoporosis.
J Clin Endocrinol Metab 1985; 61: 952-956
71. Grissom LE, Harcke HT: Radiographic features of bisphosphonate
therapy in pediatric patients. Pediatr Radiol 2003; 33: 226-229
72. Shaw NJ, Bishop NJ: Bisphosphonate treatment of bone disease.
Arch Dis Child 2005; 90: 494-499
73. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A:
Transplacental effects of bisphosphonates on fetal skeletal
ossification and mineralization in rats. Teratology 1999; 60: 68-73
74. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F:
Renal failure associated with intravenous diphosphonates. Lancet
1983; 1:471
75. Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier
S, Biour M, Massy Z: Zoledronic acid and renal toxicity: Data from
French adverse effect reporting database. Ann Pharmacother 2005;
39: 1194-1197
76. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR,
Jagannath S, Kuhn JA, Dratch AD, D’Agati VD: Collapsing focal
segmental glomerulosclerosis following treatment with high-dose
pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172
77. Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D:
Short-term, high-dose pamidronate-induced acute tubular necrosis:
The postulated mechanisms of bisphosphonate nephrotoxicity. Am
J Kidney Dis 2003; 41: E18
78. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM,
Wallach J, Walker PD: Podocyte injury associated glomerulopathies
induced by pamidronate. Kidney Int 2004; 65: 634-641
141
Yıldız N ve Alpay H: Bifosfonatların Pediatrik Nefrolojide Kullanımı
Pediatride Bifosfonatlar
Türk N efroloji D iyaliz ve Transplantasyon D ergisi
Turkish Nephrology, Dialysis and Transplantation Journal
Turk Neph Dial Transpl 2011; 20 (2): 132-141
79. Kunin M, Kopolovic J, Avigdor A, Holtzman EJ: Collapsing
glomerulopathy induced by long-term treatment with standard-dose
pamidronate in a myeloma patient. Nephrol Dial Transplant 2004;
19: 723-726
80. Von Moos R: Bisphosphonate treatment recommendations for
oncologists. Oncologist 2005;10: 19-24
81. Högler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT:
Short-term safety assessment in the use of intravenous zoledronic
acid in children. J Pediatr 2004; 145: 701-704
82. Von Moos R, Caspar CB, Thürlimann B, Angst R, Inauen R, Greil R,
Bergstrom B, Schmieding K, Pecherstorfer M: Renal safety profiles
of ibandronate 6 mg infused over 15 and 60 min: A randomized,
open-label study. Ann Oncol 2008; 19: 1266-1270
83. Body JJ, Diel IJ, Tripathy D, Bergstrom B: Intravenous ibandronate
does not affect time to renal function deterioration in patients with
skeletal metastases from breast cancer: Phase III trial results. Eur J
Cancer Care 2006; 15: 299-302
84. Perazella MA, Markowitz GS: Bisphosphonate nephrotoxicity.
Kidney Int 2008; 74: 1385-1393
85. Munns CF, Rauch F, Mier RJ, Glorieux FH: Respiratory distress
with pamidronate treatment in infants with severe osteogenesis
imperfecta. Bone 2004; 35: 231-234
86. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I,
Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou
C, Terpos E, Dimopoulos MA: Osteonecrosis of the jaw in cancer
after treatment with bisphosphonates: Incidence and risk factors. J
Clin Oncol 2005; 23: 8580-8587
87. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S:
Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349:
457-463

Thank you for copying data from http://www.arastirmax.com